Ultragenyx Pharmaceutical Ownership | Who Owns Ultragenyx Pharmaceutical?


OverviewForecastRevenueFinancialsChartTranscripts

Ultragenyx Pharmaceutical Ownership Summary


Ultragenyx Pharmaceutical is owned by 104.59% institutional investors, 3.62% insiders. Vanguard group is the largest institutional shareholder, holding 11.60% of RARE shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.05% of its assets in Ultragenyx Pharmaceutical shares.

RARE Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockUltragenyx Pharmaceutical104.59%3.62%-8.22%
SectorHealthcare Stocks 46.98%7.90%45.12%
IndustryBiotech Stocks 44.85%7.67%47.48%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vanguard group9.78M11.60%$401.98M
Blackrock5.60M6.65%$230.30M
Sands capital management5.35M6.35%$220.08M
Wellington management group llp4.56M5.41%$187.26M
Rtw investments, lp3.26M3.87%$133.98M
Price t rowe associates inc /md/2.99M3.55%$122.97M
State street2.70M3.20%$110.85M
Clearbridge investments2.35M2.79%$96.74M
Alkeon capital management2.24M2.66%$92.14M
Federated hermes2.11M2.50%$86.60M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Vestal point capital, lp1.80M5.52%$73.98M
Cutter capital management, lp365.00K4.53%$15.00M
Eagle health investments lp524.50K3.78%$21.56M
First light asset management963.15K3.47%$39.59M
Suvretta capital management2.06M3.11%$84.72M
Blue owl capital lp268.24K3.07%$11.02M
Privium fund management b.v.251.60K2.63%$10.31M
Bioimpact capital380.55K2.43%$15.64M
Rock springs capital management lp1.92M2.38%$79.08M
Rtw investments, lp3.26M2.07%$133.98M

Top Buyers

HolderShares% AssetsChange
Vestal point capital, lp1.80M5.52%1.69M
Sands capital management5.35M0.65%1.50M
Vanguard group9.78M0.01%1.08M
Norges bank1.00M0.01%1.00M
Adage capital partners gp1.13M0.09%975.00K

Top Sellers

HolderShares% AssetsChange
Rtw investments, lp3.26M2.07%-3.83M
Price t rowe associates inc /md/2.99M0.01%-576.91K
Pictet asset management sa556.82K0.03%-479.56K
Eventide asset management---359.00K
Mirae asset global investments2.48K0.00%-228.28K

New Positions

HolderShares% AssetsChangeValue
Norges bank1.00M0.01%1.00M$41.20M
Frazier life sciences management425.00K0.82%425.00K$17.47M
Cutter capital management, lp365.00K4.53%365.00K$15.00M
D. e. shaw203.44K0.01%203.44K$8.36M
Lmr partners llp145.00K0.05%145.00K$5.96M

Sold Out

HolderChange
Cibc private wealth group-19.00
Riggs asset managment-22.00
Anfield capital management-40.00
First premier bank-53.00
Sunbelt securities-86.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2024277-0.72%88,159,11611.50%1041.10%1637.95%75-5.06%
Mar 31, 202427911.16%79,067,043-1.61%970.78%1518.63%793.95%
Dec 31, 20232516.81%80,357,49814.79%1121.15%13919.83%761.33%
Sep 30, 2023235-7.11%70,004,4680.74%981.01%116-13.43%75-6.25%
Jun 30, 20232536.75%69,488,3241.14%981.04%13414.53%80-1.23%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv2.81M3.05%92.60K
Sands Capital Select Growth TE Inst EQ2.41M2.62%-728.17K
Vanguard Small Cap Index2.19M2.38%11.24K
Vanguard Explorer Inv1.98M2.15%-213.31K
Vanguard Institutional Extnd Mkt Idx Tr1.38M1.50%-6.83K
Hartford MidCap Y1.31M1.42%-17.45K
Vanguard Small Cap Growth Index Inv1.21M1.31%5.48K
DWS Vermögensbildungsfonds I LD1.18M1.28%-
Federated Hermes Kaufmann Small Cap Grow1.09M1.18%-
Federated Hermes Kaufmann Small Cap A1.09M1.18%-

Recent Insider Transactions


DateNameRoleActivityValue
Oct 10, 2024Horn Howard Chief Financial OfficerSell$393.85K
Sep 03, 2024KAKKIS EMIL D President & CEOSell$1.12M
Sep 03, 2024Huizenga Theodore Alan SVP, Chief Accounting OfficerSell$5.11K
Aug 06, 2024KAKKIS EMIL D President & CEOSell$1.00M
Jul 02, 2024Sanders Corazon (Corsee) D.-Sell$23.93K

Insider Transactions Trends


DateBuySell
2024 Q4-1
2024 Q3-4
2024 Q2-4
2024 Q1-11
2023 Q4-3

RARE Ownership FAQ


Who Owns Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical shareholders are primarily institutional investors at 104.59%, followed by 3.62% insiders and -8.21% retail investors. The average institutional ownership in Ultragenyx Pharmaceutical's industry, Biotech Stocks , is 44.85%, which Ultragenyx Pharmaceutical exceeds.

Who owns the most shares of Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical’s largest shareholders are Vanguard group (9.78M shares, 11.60%), Blackrock (5.6M shares, 6.65%), and Sands capital management (5.35M shares, 6.35%). Together, they hold 24.60% of Ultragenyx Pharmaceutical’s total shares outstanding.

Does Blackrock own Ultragenyx Pharmaceutical?

Yes, BlackRock owns 6.65% of Ultragenyx Pharmaceutical, totaling 5.6M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 230.3M$. In the last quarter, BlackRock increased its holdings by 367.61K shares, a 7.02% change.

Who is Ultragenyx Pharmaceutical’s biggest shareholder by percentage of total assets invested?

Vestal point capital, lp is Ultragenyx Pharmaceutical’s biggest shareholder by percentage of total assets invested, with 5.52% of its assets in 1.8M Ultragenyx Pharmaceutical shares, valued at 73.98M$.

Who is the top mutual fund holder of Ultragenyx Pharmaceutical shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Ultragenyx Pharmaceutical shares, with 3.05% of its total shares outstanding invested in 2.81M Ultragenyx Pharmaceutical shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools